Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.63 |
| ▸ | ASPH | Q12797 | 3/20 | 0.63 |
| ▸ | KDM8 | Q8N371 | 2/20 | 0.63 |
| ▸ | KMO | O15229 | 7/20 | 0.40 |
| ▸ | P4HTM | Q9NXG6 | 4/20 | 0.39 |
| ▸ | P4HA1 | P13674 | 1/20 | 0.39 |
| ▸ | MIF | P14174 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | KDM6B | O15054 | 1/20 | 0.38 |
| ▸ | TET3 | O43151 | 1/20 | 0.38 |
| ▸ | KDM4A | O75164 | 1/20 | 0.38 |
| ▸ | BBOX1 | O75936 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | KDM5A | P29375 | 1/20 | 0.38 |
| ▸ | KDM5C | P41229 | 1/20 | 0.38 |
| ▸ | KDM4D | Q6B0I6 | 1/20 | 0.38 |
| ▸ | TET2 | Q6N021 | 1/20 | 0.38 |
| ▸ | ALKBH5 | Q6P6C2 | 1/20 | 0.38 |
| ▸ | KDM7A | Q6ZMT4 | 1/20 | 0.38 |
| ▸ | TET1 | Q8NFU7 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18036225 | 0.84 | KDM4E (0.44) | KDM4EASPHKDM8SMN1; SMN2KMT2A | |
| SCHEMBL27164868 | 0.81 | KDM4E (0.70) | KDM4EASPHKDM8KMOP4HTM | |
| SCHEMBL3135116 | 0.81 | KDM4E (0.48) | KDM4EASPHKDM8KMOP4HTM | |
| SCHEMBL31052884 | 0.81 | KDM4E (0.48) | KDM4EASPHKDM8KMOP4HTM | |
| SCHEMBL31052887 | 0.81 | KDM4E (0.48) | KDM4EASPHKDM8KMOP4HTM | |
| SCHEMBL31474566 | 0.79 | KDM4E (0.68) | KDM4EASPHKDM8KMOP4HTM | |
| SCHEMBL24196273 | 0.78 | PIK3CA (0.40) | KDM4EASPHKDM8 | |
| SCHEMBL20638703 | 0.78 | MAPK1 (0.50) | KDM4EASPHKDM8ALDH1A1MAPT | |
| SCHEMBL21989562 | 0.78 | KDM4E (0.42) | KDM4EASPHKDM8ALDH1A1MAPT | |
| SCHEMBL5917874 | 0.78 | KDM4E (0.46) | KDM4EASPHKDM8P4HTMP4HA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11925631-B2 | Substituted 6-azabenzimidazole compounds | GILEAD SCIENCES, INC. (US) | 2024-03-12 | — | — | US | disclosed |
| CN-117105933-A | Substituted 6-azabenzimidazole compounds having HPK1 inhibitory activity | 吉利德科学公司 | 2023-11-24 | — | — | CN | disclosed |
| CN-112969505-B | Substituted 6-azabenzimidazole compounds having HPK1 inhibitory activity | 吉利德科学公司 | 2023-11-14 | — | — | CN | disclosed |
| US-20230013585-A1 | SUBSTITUTED 6-AZABENZIMIDAZOLE COMPOUNDS | GILEAD SCIENCES, INC. | 2023-01-19 | — | — | US | disclosed |
| US-20230013585-A1 | SUBSTITUTED 6-AZABENZIMIDAZOLE COMPOUNDS | GILEAD SCIENCES, INC. | 2023-01-19 | — | — | US | disclosed |
| EP-3873608-A1 | SUBSTITUTED 6-AZABENZIMIDAZOLE COMPOUNDS HAVING HPK1 INHIBITORY ACTIVITY | GILEAD SCIENCES, INC. (US) | 2021-09-08 | — | — | EP | disclosed |
| US-11071730-B2 | Substituted 6-azabenzimidazole compounds | GILEAD SCIENCES, INC. (US) | 2021-07-27 | — | — | US | disclosed |
| US-11071730-B2 | Substituted 6-azabenzimidazole compounds | GILEAD SCIENCES, INC. (US) | 2021-07-27 | — | — | US | disclosed |
| CN-112969505-A | Substituted 6-azabenzimidazole compounds having HPK1 inhibiting activity | 吉利德科学公司 | 2021-06-15 | — | — | CN | disclosed |
| US-20200171020-A1 | SUBSTITUTED 6-AZABENZIMIDAZOLE COMPOUNDS | GILEAD SCIENCES, INC. | 2020-06-04 | — | — | US | disclosed |
| US-20200171020-A1 | SUBSTITUTED 6-AZABENZIMIDAZOLE COMPOUNDS | GILEAD SCIENCES, INC. | 2020-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11925631-B2 | Substituted 6-azabenzimidazole compounds | CDK6, HIPK1, DCK | KDM4E 1027/4885ASPH 3815/4885KDM8 949/4885 |
| US-11071730-B2 | Substituted 6-azabenzimidazole compounds | CDK6, HIPK1, DCK | KDM4E 1027/4885ASPH 3815/4885KDM8 949/4885 |
| US-20200171020-A1 | SUBSTITUTED 6-AZABENZIMIDAZOLE COMPOUNDS | CDK6, HIPK1, DCK | KDM4E 1027/4885ASPH 3815/4885KDM8 949/4885 |
| US-20230013585-A1 | SUBSTITUTED 6-AZABENZIMIDAZOLE COMPOUNDS | CDK6, HIPK1, DCK | KDM4E 1027/4885ASPH 3815/4885KDM8 949/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.